Sygnature Discovery

Nottingham, United Kingdom

Sygnature Discovery

Nottingham, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Fragment-Based Drug Discovery (FBDD) Market Analysis: Services, End Users, Growth Trends and Forecast to 2020, New Research by iHealthcareAnalyst, Inc. Fragment-Based Drug Discovery Market by Service Type (FBDD and HTS Comparative Analysis, Fragment Screening, Biophysical Techniques, NMR Spectroscopy, DSF Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, SPR, Bilayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, Biochemical Assays, Non-Biophysical Techniques, Fragment Optimization), End Users (Academic and Research Institutes, Biopharmaceuticals, CROs) 2016-2020. Maryland Heights, MO, February 22, 2017 --( Browse Fragment-Based Drug Discovery Market by Service Type or Components (Comparative Analysis of FBDD and HTS, Fragment Screening, Biophysical Techniques, NMR Spectroscopy, DSF Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, SPR, Bilayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, Biochemical Assays, Non-Biophysical Techniques, Fragment Optimization), and End Users (Academic and Research Institutes, Biopharmaceutical Companies, and CROs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/ Fragment-based lead discovery (FBLD) also known as fragment-based drug discovery (FBDD) is a method used for finding lead compounds as part of the drug discovery process. It is based on identifying small chemical fragments, which may bind only weakly to the biological target, and then growing them or combining them to produce a lead with a higher affinity. The global fragment-based drug discovery market segmentation is based on service types or components (comparative analysis of FBDD and HTS, fragment screening, biophysical techniques, NMR spectroscopy, DSF assay, fluorescence polarization, isothermal titration calorimetry, X-ray crystallography, SPR, bilayer interferometry, mass spectrometry, capillary electrophoresis, biochemical assays, non-biophysical techniques, fragment optimization), and end users (academic and research institutes, biopharmaceutical companies, and CROs). The global fragment-based drug discovery market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global fragment-based drug discovery market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global fragment-based drug discovery market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global fragment-based drug discovery market and included in this report are Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Emerald BioStructures, Evotec A.G., Kinetic Discovery, Proteros Fragments, Structure Based Design, Sygnature Discovery, and Sprint Bioscience AB. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 22, 2017 --( PR.com )-- The global fragment-based drug discovery market is estimated to reach USD 650 Million in 2020, growing at a CAGR of 10.6% from 2016 to 2020. Increasing adoption of fragment-based screening programs by most of the major pharmaceutical companies, increasing availability of more assay options in research departments of most pharmaceutical and biotechnology companies for high hit rates of fragment-based screens are the major drivers of the global fragment-based drug discovery market, and are likely continue this trend during the forecast period.Browse Fragment-Based Drug Discovery Market by Service Type or Components (Comparative Analysis of FBDD and HTS, Fragment Screening, Biophysical Techniques, NMR Spectroscopy, DSF Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, SPR, Bilayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, Biochemical Assays, Non-Biophysical Techniques, Fragment Optimization), and End Users (Academic and Research Institutes, Biopharmaceutical Companies, and CROs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/Fragment-based lead discovery (FBLD) also known as fragment-based drug discovery (FBDD) is a method used for finding lead compounds as part of the drug discovery process. It is based on identifying small chemical fragments, which may bind only weakly to the biological target, and then growing them or combining them to produce a lead with a higher affinity.The global fragment-based drug discovery market segmentation is based on service types or components (comparative analysis of FBDD and HTS, fragment screening, biophysical techniques, NMR spectroscopy, DSF assay, fluorescence polarization, isothermal titration calorimetry, X-ray crystallography, SPR, bilayer interferometry, mass spectrometry, capillary electrophoresis, biochemical assays, non-biophysical techniques, fragment optimization), and end users (academic and research institutes, biopharmaceutical companies, and CROs).The global fragment-based drug discovery market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global fragment-based drug discovery market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global fragment-based drug discovery market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global fragment-based drug discovery market and included in this report are Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Emerald BioStructures, Evotec A.G., Kinetic Discovery, Proteros Fragments, Structure Based Design, Sygnature Discovery, and Sprint Bioscience AB.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


Farinha C.M.,University of Lisbon | King-Underwood J.,Sygnature Discovery | Sousa M.,University of Lisbon | Correia A.R.,New University of Lisbon | And 7 more authors.
Chemistry and Biology | Year: 2013

Cystic fibrosis is mostly caused by the F508del mutation, which impairs CFTR protein from exiting the endoplasmic reticulum due to misfolding. VX-809 is a small molecule that rescues F508del-CFTR localization, which recently went into clinical trial but with unknown mechanism of action (MoA). Herein, we assessed if VX-809 is additive or synergistic with genetic revertants of F508del-CFTR, other correctors, and low temperature to determine its MoA. We explored and integrated those various agents in combined treatments, showing how they add to each other to identify their complementary MoA upon correction of F508del-CFTR. Our experimental and modeling data, while compatible with putative binding of VX-809 to NBD1:ICL4 interface, also indicate scope for further synergistic F508del-CFTR correction by other compounds at distinct conformational sites/cellular checkpoints, thus suggesting requirement of combined therapies to fully rescue F508del-CFTR. © 2013 Elsevier Ltd.


PubMed | Universtitat Duisburg Essen and Sygnature Discovery
Type: Journal Article | Journal: Bioorganic & medicinal chemistry | Year: 2015

Scaffolds of natural products represent promising starting points for the development of focused compound libraries. Here, we describe the development of a synthetic route to a compound library based on the hexahydropyrrolo indole (HPI) scaffold, the denoting structural motif of the HPI natural product family. To this end, a two-step approach consisting of a batch synthesis of an advanced functionalizable HPI intermediate followed by the establishment of reaction conditions that allow derivatization of this scaffold at three different positions is described. Subsequently, the optimized methods were applied to the synthesis of a 276-member library.


Storr T.E.,University of Nottingham | Cully S.J.,University of Nottingham | Rawling M.J.,University of Nottingham | Lewis W.,University of Nottingham | And 3 more authors.
Bioorganic and Medicinal Chemistry | Year: 2015

The application of a tandem condensation/cyclisation/[3+2]-cycloaddition/elimination reaction gives an sp3-rich tricyclic pyrazoline scaffold with two ethyl esters in a single step from a simple linear starting material. The successive hydrolysis and cyclisation (with Boc anhydride) of these 3-dimensional architectures, generates unprecedented 16-membered macrocyclic bisanhydrides (characterised by XRD). Selective amidations could then be achieved by ring opening with a primary amine followed by HATU-promoted amide coupling to yield an sp3-rich natural product-like library. © 2015 Elsevier B.V. All rights reserved.


Karawajczyk A.,Taros Chemicals GmbH and Co. KG | Giordanetto F.,Taros Chemicals GmbH and Co. KG | Benningshof J.,Mercachem | Hamza D.,Sygnature Discovery | And 7 more authors.
Drug Discovery Today | Year: 2015

High-throughput screening (HTS) represents a major cornerstone of drug discovery. The availability of an innovative, relevant and high-quality compound collection to be screened often dictates the final fate of a drug discovery campaign. Given that the chemical space to be sampled in research programs is practically infinite and sparsely populated, significant efforts and resources need to be invested in the generation and maintenance of a competitive compound collection. The European Lead Factory (ELF) project is addressing this challenge by leveraging the diverse experience and know-how of academic groups and small and medium enterprises (SMEs) engaged in synthetic and/or medicinal chemistry. Here, we describe the novelty, diversity, structural complexity, physicochemical characteristics and overall attractiveness of this first batch of ELF compounds for HTS purposes.


St-Gallay S.A.,Sygnature Discovery | Sambrook-Smith C.P.,Sygnature Discovery
Journal of Computer-Aided Molecular Design | Year: 2016

Computer-aided drug design encompasses a wide variety of tools and techniques, and can be implemented with a range of organisational structures and focus in different organisations. Here we outline the computational chemistry skills within Sygnature Discovery, along with the software and hardware at our disposal, and briefly discuss the methods that are not employed and why. The goal of the group is to provide support for design and analysis in order to improve the quality of compounds synthesised and reduce the timelines of drug discovery projects, and we reveal how this is achieved at Sygnature. Impact on medicinal chemistry is vital to demonstrating the value of computational chemistry, and we discuss the approaches taken to influence the list of compounds for synthesis, and how we recognise success. Finally we touch on some of the areas being developed within the team in order to provide further value to the projects and clients. © 2016 Springer International Publishing Switzerland


PubMed | Sygnature Discovery
Type: | Journal: Journal of computer-aided molecular design | Year: 2016

Computer-aided drug design encompasses a wide variety of tools and techniques, and can be implemented with a range of organisational structures and focus in different organisations. Here we outline the computational chemistry skills within Sygnature Discovery, along with the software and hardware at our disposal, and briefly discuss the methods that are not employed and why. The goal of the group is to provide support for design and analysis in order to improve the quality of compounds synthesised and reduce the timelines of drug discovery projects, and we reveal how this is achieved at Sygnature. Impact on medicinal chemistry is vital to demonstrating the value of computational chemistry, and we discuss the approaches taken to influence the list of compounds for synthesis, and how we recognise success. Finally we touch on some of the areas being developed within the team in order to provide further value to the projects and clients.


PubMed | Anglia, Sygnature Discovery and University of Nottingham
Type: Journal Article | Journal: Bioorganic & medicinal chemistry | Year: 2016

In order to address the current downturn in the drug discovery pipeline, initiatives are being undertaken to synthesise screening libraries of sp


PubMed | Sygnature Discovery and Corcept Therapeutics
Type: Journal Article | Journal: Bioorganic & medicinal chemistry letters | Year: 2015

We report the further optimization of our series 1H-pyrazolo[3,4-g]hexahydro-isoquinoline sulfonamides as GR antagonists. By incorporating a heteroaryl ketone group at the ring junction, we have obtained compounds with excellent functional GR antagonism. Optimization of the sulfonamide substituent has provided compounds with a very desirable overall profile, including minimal hERG activity, good bioavailability and in vivo efficacy.


PubMed | Agilent Technologies, University of Liverpool, In Vivo Assays Ltd, Imperial College London and 3 more.
Type: | Journal: Archives of toxicology | Year: 2016

The distribution, metabolism, excretion and hepatic effects of the human hepatotoxin fenclozic acid were investigated following single oral doses of 10mg/kg to normal and bile duct-cannulated male C57BL/6J mice. Whole body autoradiography showed distribution into all tissues except the brain, with radioactivity still detectable in blood, kidney and liver at 72h post-dose. Mice dosed with [

Loading Sygnature Discovery collaborators
Loading Sygnature Discovery collaborators